Next Article in Journal
Proteins in Autophagic Machinery
Next Article in Special Issue
Neuroglobin in Retinal Neurodegeneration: A Potential Target in Therapeutic Approaches
Previous Article in Journal
Does Schistosoma Mansoni Facilitate Carcinogenesis?
Previous Article in Special Issue
Role of Neuroglobin in the Neuroprotective Actions of Estradiol and Estrogenic Compounds
Article

Neuroglobin: A New Possible Marker of Estrogen-Responsive Breast Cancer

1
Department of Science, University Roma Tre, Viale Guglielmo Marconi 446, I-00146 Roma, Italy
2
Department of Biosciences and Territory, University of Molise, Contrada Fonte Lappone, 86090 Pesche (IS), Italy
3
Division of Senology, Belcolle Hospital, Str. Sammartinese, 01100 Viterbo, Italy
*
Authors to whom correspondence should be addressed.
Present address: Santo Spirito in Sassia Hospital, Lungotevere in Sassia, 1, 00193 Roma, Italy.
Academic Editor: Satoshi Inoue
Cells 2021, 10(8), 1986; https://doi.org/10.3390/cells10081986
Received: 2 July 2021 / Revised: 30 July 2021 / Accepted: 4 August 2021 / Published: 5 August 2021
(This article belongs to the Special Issue Neuroglobin from Brain Protection to Cancer Progression)
The expression of the α-subtype of Estrogen Receptor (ERα) characterizes most breast cancers (more than 75%), for which endocrine therapy is the mainstay for their treatment. However, a high percentage of ERα+ breast cancers are de novo or acquired resistance to endocrine therapy, and the definition of new targets for improving therapeutic interventions and the prediction of treatment response is demanding. Our previous data identified the ERα/AKT/neuroglobin (NGB) pathway as a common pro-survival process activated in different ERα breast cancer cell lines. However, no in vivo association between the globin and the malignity of breast cancer has yet been done. Here, we evaluated the levels and localization of NGB in ERα+ breast ductal carcinoma tissue of different grades derived from pre-and post-menopausal patients. The results indicate a strong association between NGB accumulation, ERα, AKT activation, and the G3 grade, while no association with the menopausal state has been evidenced. Analyses of the data set (e.g., GOBO) strengthen the idea that NGB accumulation could be linked to tumor cell aggressiveness (high grade) and resistance to treatment. These data support the view that NGB accumulation, mainly related to ER expression and tumor grade, represents a compensatory process, which allows cancer cells to survive in an unfavorable environment. View Full-Text
Keywords: AKT; breast cancer survival; ductal infiltrating adenocarcinoma; estrogen receptor α; neuroglobin; tumor microenvironment AKT; breast cancer survival; ductal infiltrating adenocarcinoma; estrogen receptor α; neuroglobin; tumor microenvironment
Show Figures

Figure 1

MDPI and ACS Style

Solar Fernandez, V.; Fiocchetti, M.; Cipolletti, M.; Segatto, M.; Cercola, P.; Massari, A.; Ghinassi, S.; Cavaliere, F.; Marino, M. Neuroglobin: A New Possible Marker of Estrogen-Responsive Breast Cancer. Cells 2021, 10, 1986. https://doi.org/10.3390/cells10081986

AMA Style

Solar Fernandez V, Fiocchetti M, Cipolletti M, Segatto M, Cercola P, Massari A, Ghinassi S, Cavaliere F, Marino M. Neuroglobin: A New Possible Marker of Estrogen-Responsive Breast Cancer. Cells. 2021; 10(8):1986. https://doi.org/10.3390/cells10081986

Chicago/Turabian Style

Solar Fernandez, Virginia, Marco Fiocchetti, Manuela Cipolletti, Marco Segatto, Paolo Cercola, Annalisa Massari, Sabrina Ghinassi, Francesco Cavaliere, and Maria Marino. 2021. "Neuroglobin: A New Possible Marker of Estrogen-Responsive Breast Cancer" Cells 10, no. 8: 1986. https://doi.org/10.3390/cells10081986

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop